Cytomegalovirus disease in solid organ transplant recipients: Advances lead to new challenges and opportunities

Current Opinion in Organ Transplantation

Volumn 12, Issue 6, 2007, Pages 610-617

  Eid, Albert J ^a   Razonable, Raymund R ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antivirals; Immunity; Outcomes; Prevention; Transplantation

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; GANCICLOVIR; IMMUNOGLOBULIN G; PLACEBO; VALGANCICLOVIR;

ADAPTIVE IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG INHIBITION; GRAFT REJECTION; HUMAN; INNATE IMMUNITY; META ANALYSIS; MORBIDITY; MORTALITY; ORGAN DONOR; ORGAN TRANSPLANTATION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 36248983615     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f0d386     Document Type: Review

References (70)

1. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60-65.
2. Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2007; 19 May [E pub ahead of print]. This single center study demonstrated the rare occurrence of CMV retinitis as the manifestation of CMV disease. The severity of visual findings at the onset of disease may predict eventual outcome.
3. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307-1314. This large single center study identified cytomegalovirus as an important marker for the occurrence of opportunistic Nocardia infection after transplantation: potentially another indirect effect of CMV.
4. Razonable RR, Brown RA, Humar A, et al. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005; 192:1349-1354.
5. Razonable RR, Paya CV. The impact of human herpesvirus-6 and 7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8:651-658.
6. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17:114-120.
7. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35:974-981.
8. Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13:130-135. This study investigated the potential interactions between hepatitis C virus and cytomegalovirus. In their cohort, the reported bidirectional association between the two viruses was not observed.
9. Humar A, Washburn K, Freeman R, et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl (in press).
10. Fearon WF, Potena L, Hirohata A, et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 2007; 83:700-705. In this study, transplant recipients who were CMV seropositive and those who did not receive aggressive anti-CMV prophylaxis were significantly at greater risk of negative vascular remodeling leading to greater lumen loss after cardiac transplantation.
11. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115:1798-1805. In this study of children, recipient CMV seropositivity was the only independent predictor of coronary artery disease, all-cause mortality, and coronary death.
12. Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc 2007; 39:990-992. This study demonstrated in a multivariable analysis that the presence of CMV infection may be a triggering factor for atherosclerotic events after kidney transplantation.
13. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006; 17:S291-S295. The role of CMV as a modifiable risk factor for the occurrence of new-onset diabetes after transplantation was highlighted in this report.
14. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006; 82:S15-S17. In a series of prospective studies of kidney transplant recipients who did not receive prophylaxis or preemptive therapy, CMV was found to be independent risk factors for allograft rejection and new-onset diabetes mellitus within 100 days after transplantation.
15. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82:398-405. In this study of heart transplant recipients, the use of (val)ganciclovir plus CMVIG reduces viral levels, acute rejection, and allograft vascular disease.
16. Hellinger WC, Bonatti H, Machicao VI, et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006; 81:1029-1033.
17. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21:309-313. In this study of 471 kidney transplant recipients, the occurrence of CMV was an independent predictor of mortality.
18. Helantera I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19:893-900.
19. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-1652.
20. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204-212.
21. Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7:471-475.
22. Razonable RR, Paya CV. Infections and allograft rejection: intertwined complications of organ transplantation. Swiss Med Wkly 2005; 135:571-573.
23. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-1464.
24. Kijpittayarit S, Eid AJ, Kremers W, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant (in press).
25. Kijpittayarit S, Eid AJ, Pedersen R, et al. Delayed onset primary CMV disease after liver transplantation. Liver Transplant (in press).
26. Song AT, Abdala E, Bonazzi PR, et al. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review. Braz J Infect Dis 2006; 10:132-138.
27. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006; 38:1922-1923.
28. Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44:1315-1320. In this study of 92 liver transplant recipients, the presence of homozygous polymorphism in Toll-like receptor 2 was significantly associated with higher levels of CMV replication and higher incidence of CMV disease.
29. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83:1493-1500. In a univariate analysis, this study demonstrated that low-mannose binding lectin genotypes were associated with reactivation CMV disease while Toll-like receptor 4 mutation was associated with higher risk of primary CMV infection. In a multivariate analysis, Toll-like receptor 4 mutation was an independent factor associated with CMV disease.
30. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454-2461.
31. Manuel O, Pascual M, Trendelenburg M, et al. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83:359-362. In this analysis, the proportion of mannose-binding lectin deficiency was higher in kidney transplant recipients who developed CMV infection and disease than in those who did not have CMV infection.
32. Loeffler J, Steffens M, Arlt EM, et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 2006; 44:1847-1850.
33. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006; 114:1608-1615.
34. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-2364.
35. La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195:633-644.
36. Cytomegalovirus. Am J Transplant 2004; 4 (Suppl 10):51-58.
37. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-880.
38. Small LN, Lau J, Snydman DR. Preventing postorgan transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869-880.
39. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-2115.
40. Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007; (2):CD005129.
41. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-620.
42. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5:1462-1468.
43. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81:1106-1111. As the multicenter clinical trial comparing 100 versus 200 days of antiviral prophylaxis is being conducted, this study may provide some insights into the anticipated outcomes. Longer prophylaxis was associated with lower risk of CMV disease.
44. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006; 50:3470-3472.
45. Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37:124-127. This study described the potential clinical utility of the novel drug maribavir for the treatment of CMV that is resistant to the standard anti-CMV drugs.
46. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187:1801-1808.
47. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-860.
48. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007; 83:874-882.
49. Emery VC, Hassan-Walker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185:1723-1728.
50. Lopau K, Greser A, Wanner C. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin Transplant 2007; 21:80-85.
51. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82:30-35.
52. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134-2143.
53. Eid AJ, Razonable RR. Valganciclovir for the treatment of CMV retinitis in patients with AIDS. Expert Review of Ophthalmology 2007; 2:351-361.
54. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191:89-92.
55. Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005; 192:1154-1157.
56. Humar A, Kumar D, Gray M, et al. A prospective assessment of cytomegalovirus immune evasion gene transcription profiles in transplant patients with cytomegalovirus infection. Transplantation 2007; 83:1200-1206.
57. Asberg A, Humar A, Rollag H, et al. on behalf on the VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106-2113. This abstract describes the results of the comparative trial of valganciclovir versus intravenous ganciclovir for the treatment of CMV disease in solid organ transplant recipients.
58. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186:829-833.
59. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181:717-720.
60. Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9:203-210.
61. Ruell J, Barnes C, Mutton K, et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant 2007; 40:55-61.
62. Nogueira E, Ozaki KS, Tomiyama H, et al. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients. Int Immunopharmacol 2006; 6:2031-2037.
63. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17:265-273.
64. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20-27.
65. Boivin G, Goyette N, Gilbert C, et al. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77:425-429.
66. Boivin G, Gilbert C, Gaudreau A, et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184:1598-1602.
67. Mendez JC, Sia IG, Tau KR, et al. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 1999; 67:755-757.
68. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes. Clin Transplant (in press).
69. Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8:38-43.
70. Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007; 196:91-94.